Cargando…
Efficacy, safety and effect on gene expression profiling of anakinra in systemic-onset juvenile idiopathic arthritis: final results of a randomised, double-blind, placebo-controlled trial (ANAJIS)
Autores principales: | Quartier, P, Allantaz, F, Cimaz, R, Pillet, P, Richer, O, Desjonqueres, M, Duquesne, A, Messiaen, C, Bardin, C, Bossuyit, X, Boutten, A, Bienvenu, J, Menoni, V, Sotou-Bere, S, Neven, B, Mahloui, N, Mogenet, A, Kassai, B, Chaussabel, D, Treluyer, JM, Bresson, JL, Landais, P, Pascual, V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334078/ http://dx.doi.org/10.1186/1546-0096-6-S1-P27 |
Ejemplares similares
-
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)
por: Quartier, Pierre, et al.
Publicado: (2010) -
Efficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis
por: Nemiche, O, et al.
Publicado: (2011) -
PReS-FINAL-2111: Cytomegalovirus, Epstein Barr virus and Varicella-Zoster virus infections in children with juvenile idiopathic arthritis treated with biologics
por: Remy Piccolo, V, et al.
Publicado: (2013) -
Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes
por: Urien, Saik, et al.
Publicado: (2013) -
Anakinra in children and adults with Still’s disease
por: Vastert, Sebastiaan J, et al.
Publicado: (2019)